Cat. No.
MABL-644
Application
inhibit, therapeutic, Block
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
CNTO 888 (Carlumab)
From
Recombinant Antibody
Specificity
This antibody specifically binds human CCL2 and does not cross react with mouse CCL2 or other human CC chemokines. It is reported that CNTO 888 recognizes a conformational epitope encompassing residues 18-24 and 45-51 that overlaps the mapped receptor binding site.
Alternative Names
MCP-1; MCP1; HC11; MCAF; C-C motif chemokine 2; monocyte chemoattractant protein 1; monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; Small-inducible cytokine A2
UniProt
P13500
Immunogen
The original antibody was generated by phage display using the Human Combinatorial Antibody Library (HuCAL GOLD).
Application Notes
CCL2 is implicated in the pathogenesis of certain inflammatory diseases and cancer. Binding of CCL2 to its receptor CCR2 triggers calcium mobilization and chemotaxis. CNTO 888 is a neutralizing anti-CCL2 antibody that binds human CCL2 with high affinity of Kd=22pM and inhibits CCL2 binding to its receptor. The systemic administration of anti-CCL2 neutralizing antibodies (CNTO888 and C1142) significantly retarded tumor growth and attenuated CD68+ macrophage infiltration, which was accompanied by a significant decrease in microvascular density (PMID: 17710158). Phase 1 trials in 44 patients with solid tumors concluded that CNTO888 was well tolerated in individuals with evidence of transient free CCL2 suppression and preliminary antitumor activity (PMID: 23385782). This antibody was also capable of inhibiting growth of breast cancer when administered individually or as a cocktail (Campion et al, 2009). A phase 2 study in 46 patients with castration-resistant prostate cancer (CRPC) concluded that carlumab was well-tolerated but did not block the CCL2/CCR2 axis or show antitumor activity as a single agent in metastatic CRPC (PMID: 22907596).
Antibody First Published
Loberg et al. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. (2007); 9(7): 556–562.PMID:17710158
Note on publication
Describes the use of this antibody for retarding the tumor growth in prostrate cancer.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
